Your browser doesn't support javascript.
Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Klebanov, Nikolai; Pahalyants, Vartan; Murphy, William S; Theodosakis, Nicholas; Zubiri, Leyre; Klevens, R Monina; Kwatra, Shawn G; Lilly, Evelyn; Reynolds, Kerry L; Semenov, Yevgeniy R.
  • Klebanov N; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Pahalyants V; Harvard Medical School, Boston, Massachusetts, USA.
  • Murphy WS; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Theodosakis N; Harvard Medical School, Boston, Massachusetts, USA.
  • Zubiri L; Harvard Business School, Boston, Massachusetts, USA.
  • Klevens RM; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Kwatra SG; Harvard Medical School, Boston, Massachusetts, USA.
  • Lilly E; Harvard Business School, Boston, Massachusetts, USA.
  • Reynolds KL; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Semenov YR; Harvard Medical School, Boston, Massachusetts, USA.
Oncologist ; 26(5): e898-e901, 2021 05.
Article in English | MEDLINE | ID: covidwho-1156887
ABSTRACT

OBJECTIVE:

The aim of this study was to determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs). MATERIALS AND

METHODS:

This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020.

RESULTS:

The mean age was 66.6 years, and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility.

CONCLUSION:

ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: North America Language: English Journal: Oncologist Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: Onco.13768

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: North America Language: English Journal: Oncologist Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: Onco.13768